Venkat is the President and CEO of Bionpharma. He is also a member of the board of Bionpharma. In his more than 20 years with the pharmaceutical industry, Venkat was responsible for successfully transforming the North American business of Ranbaxy. Under his leadership, the Company had grown rapidly to sales in excess of $1 billion and launched some high value generic products of brands like Lipitor®, Valtrex®, Aricept®, Imitrex®, Diovan® among others. Prior to this role, he held positions as head of the Global API business, Managing Director of Basics Gmbh, Business Development head for Europe, and setup successful businesses for Ranbaxy in multiple geographies including Ukraine, Australia, New Zealand. Venkat holds a Masters degree in Pharmacy from University of Delhi and a MBA from SP Jain School of Management, University of Mumbai.
Lavesh heads up the business development function and is also the General Counsel at Bionpharma. At Bionpharma, Lavesh manages all aspects of the Company's litigation, corporate and licensing, patent matters and compliance. For more than a decade, Lavesh practiced law at Baker & McKenzie, (Singapore and Chicago), Wilson Sonsini (Palo Alto), Kramer Levin (New York), and Weil Gotshal (New York) prior to joining Ranbaxy. In his career spanning the globe at Ranbaxy, Lavesh served as Global Head of Legal at Ranbaxy and Vice President and General Counsel for the North American operations of Ranbaxy. In this role, he led all legal aspects, including M&A, transfer pricing, litigation, licensing agreements and FDA regulatory matters. Lavesh oversaw legal victories in patent challenges & settlements for Lipitor®, Diovan® and Aricept®. Lavesh is licensed to practice law in New York, New Jersey, California and Illinois. Lavesh holds a joint Bachelors dual degree in Government and History from Claremont McKenna College. He received his Juris Doctorate from Columbia University School of Law and is fluent in several languages.
Bill is a very experienced trade sales professional and fills the role as EVP of Sales and Distribution at Bionpharma. Bill led Ranbaxy's sales and commercial operations in North America. A 30 plus year veteran of the pharmaceutical industry, he is known in the trade for his customer centric approach and knowledge of the market. Bill was instrumental in launching Ranbaxy in the US and and was instrumental in successful launches of many First-to-File generics of Lipitor®, Valtrex®, Aricept®, Diovan®, Zocor®, amongst others. Bill is respected and admired by many in the industry and is one of the founders of Bionpharma which has contributed to its growth and success.
Nath ensures that the market is supplied and products are filed as EVP of supply chain and projects. Nath has over 25 years experience in the generic pharmaceutical industry. Prior to Bionpharma, he was Vice President - supply chain, purchasing and projects for Ranbaxy in North America. In Nath's time at Ranbaxy, he oversaw building of some key manufacturing facilities across various geographies, built efficient supply chain processes for the North American market and helped develop and commercialize products. Nath holds a Masters degree in Pharmacy from Birla Institute of Technology & Science, Pilani. India.
Gaurav brings in a wealth of experience as the CFO and EVP of commercial operations at Bionpharma. In his long professional career, Gaurav was Vice President, Finance for Ranbaxy where he was responsible for all financial functions of the North American operations and was involved with managing growth of North American sales to over a billion dollars in annually. He setup Ranbaxy's North American commercial systems and controls, improved Government Pricing & tax policies, while leading efficiency projects to maximize revenue and profitability. Gaurav received a Bachelors degree in business and an MBA from University of Delhi.
Mr. Gale is the founding partner of Signet Healthcare Partners. He initiates investments and provides active management oversight to a number of the portfolio companies. He is currently the Chairman of the Board of Alpex Pharma S.A. and Pfenex Inc., and also serves on the Board of Directors of Arbor Pharmaceutical, Spepharm AG, Paladin Laboratories, IGI, Inc., and Anteis SA. Prior to founding Signet Healthcare Partners, Mr. Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, Mr. Gale's investment activities included Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals). Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal's parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co. Mr. Gale received his Masters of Business Administration from the University of Chicago.
Dr. David Goodman is Chief Executive Officer of Pharmascience, which is today the 2nd largest privately-owned pharmaceutical company in Canada. Dr. Goodman obtained his Bachelor degree in Commerce from McGill University, and his Ph.D. in pharmacology from the University of Virginia. Upon graduation, he began his career at Pharmascience in Business Development and has gained significant experience in progressively senior international and domestic roles.Under Dr. Goodman's leadership, Pharmascience has gone from being a strictly Canadian company to becoming an important player on the global stage. Pharmascience strives to be the first company to launch its generic pipeline in Canada, Europe and various markets throughout the world. Dr. Goodman's success is his belief and insistence on major and constant investment in internal and external R & D programs, as well as in employee development.
Venkat is the President and CEO of Bionpharma. He is also a member of the board of Bionpharma. In his more than 20 years with the pharmaceutical industry, Venkat was responsible for successfully transforming the North American business of Ranbaxy. Under his leadership, the Company had grown rapidly to sales in excess of $1 billion and launched some high value generic products of brands like Lipitor®, Valtrex®, Aricept®, Imitrex®, Diovan® among others. Prior to this role, he held positions as head of the Global API business, Managing Director of Basics Gmbh, Business Development head for Europe, and setup successful businesses in multiple geographies including Ukraine, Australia, New Zealand. Venkat holds a Masters degree in Pharmacy from University of Delhi and a MBA from SP Jain School of Management, University of Mumbai.
Richard (Dick) Van Duyne joined Daiichi Sankyo in 2003 as Global Head of Business Development, chairing the Senior Licensing Committee and working directly with senior management in Tokyo, the U.S. and Europe on key licensing and business development projects. He held this position until April 1, 2013, when he moved to a senior advisor role, working with the CEO on special projects. He began his career in 1979 as an associate at the law firm of White & Case in New York and Stockholm. In 1984 he joined the Legal Division of Warner-Lambert Company. He served in various capacities in the Legal Division until moving to Licensing in 1992. In 1996 he was named Vice President Licensing & Business Development, serving in that role until Warner- Lambert was acquired by Pfizer in 2000. After a brief time as co-founder of MedPointe, a specialty pharmaceutical company, Mr. Van Duyne joined Pharmacia Corporation as Senior Vice President of Corporate Development, serving in that capacity until Pharmacia was acquired by Pfizer in 2003. Mr. Van Duyne received his B.S. in Economics from the University of Pennsylvania, his M.B.A. from the Wharton Graduate Division, University of Pennsylvania and his J.D. from Stanford University.
Carole Ben-Maimon, M.D. previously served as president of Global Pharmaceuticals, Impax Laboratories generic pharmaceutical division. In this role, Dr. Ben-Maimon reported to Impax's president and chief executive officer and was responsible for expanding Impax's generic business by growing capability in the U.S. market while driving global opportunities through partnerships and actively exploring M & A opportunities. Prior to Impax, Dr. Ben-Maimon enjoyed a broad base of executive experience in the pharmaceutical industry. She was senior vice president, corporate strategy consulting to the president, chief executive officer and investors at Qualitest Pharmaceuticals, Inc. Prior to her role at Qualitest, she held executive positions with Barr Pharmaceuticals, including president and chief operating officer of Duramed Research (formerly known as Barr Research), a subsidiary of Barr Pharmaceuticals Inc. and with Teva Pharmaceuticals USA where she was senior vice president, Science and Public Policy. From 1996 to 2000, she served as senior vice president, Research and Development at Teva. She has also served as president and chief executive officer of Alita Pharmaceuticals, Inc. - a company which she founded. She served as the chairman of the board of the Generic Pharmaceutical Association from 2000 to 2003, and is also a published author of numerous scientific and clinical articles.Dr. Ben-Maimon is a graduate of Thomas Jefferson Medical College and received a bachelor of arts in biology from The University of Pennsylvania where she graduated magna cum laude. She is board certified in internal medicine, and completed clinical and research training in nephrology at Thomas Jefferson University.
Signet Healthcare partners was founded in 1998 with the establishment of the Corporate Opportunities Funds. Since 1998, they have organized three funds and completed investments in approximately 35 companies. The team is comprised of six professionals with principal offices in New York City. This team brings over 100 years experience of collective healthcare experience in the specialty pharmaceutical, medical device, private equity and investment banking businesses. For the past sixteen years, Signet Healthcare has maintained its dedicated focus to diversified healthcare investing - primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and the pharma services industries.
Our other strategic partner is Pharmascience Inc. Founded in 1983, Pharmascience is a leading manufacturer of generic drugs in a wide range of therapeutic categories. They are a privately owned company with technologically sophisticated operations designed to satisfy customer expectations for quality products and responsive service . Pharmascience's R & D laboratory and production facilities are located in Montreal, Quebec and their Canada-wide customer base includes pharmacists, drug wholesalers and major retailers. Pharmacience is the largest pharmaceutical employer in Quebec, Canada, with 1,300 employees and the third largest generic pharmaceutical company in Canada and third largest pharmaceutical company in Canada by number of prescriptions. Pharmascience enjoys a diversified portfolio of over 340 product families, both prescription and OTC with sales in more than 60 countries and is one of the largest providers of generic single-source products.
LP: Athyrium Capital Management LP is an SEC-registered asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Managing funds with over $1.7 billion of committed capital, including a $1.2 billion fund recently closed in May 2015 , Athyrium invests across all healthcare verticals including biopharmaceuticals, medical devices and products, and healthcare services. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes, including private equity, public equity, fixed income, royalties, and other structured securities. The firm's investors include public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds.